Zealand Pharma: endpoint achieved in obesity drug
(CercleFinance.com) - Boehringer Ingelheim and Zealand Pharma announced on Wednesday that their experimental treatment for obesity had achieved a 15% weight loss in phase II clinical trials.
The study met its primary endpoint after 46 weeks of treatment, tge companies said in a joint statement.
BI 456906, a GLP-1/glucagon dual agonist, is the result of a long-standing collaboration between German pharmaceutical group Boehringer Ingelheim and Danish biotech Zealand Pharma.
The phase 2 study will evaluate it in overweight and obese people with a BMI of 27 kg/m2 or more who do not have diabetes.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The study met its primary endpoint after 46 weeks of treatment, tge companies said in a joint statement.
BI 456906, a GLP-1/glucagon dual agonist, is the result of a long-standing collaboration between German pharmaceutical group Boehringer Ingelheim and Danish biotech Zealand Pharma.
The phase 2 study will evaluate it in overweight and obese people with a BMI of 27 kg/m2 or more who do not have diabetes.
Copyright (c) 2023 CercleFinance.com. All rights reserved.